---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-050813"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-19T00:04:53.472103+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD amends CEO Walker's employment; enters consulting agreement with former CFO Donegan

## Summary
- CEO Walker's base salary increased to $500k after Apr 15, 2023; receives $20,909 lump-sum bonus and 70,000 RSUs.
- Enhanced severance: 18 months salary, 1.5x target bonus, 24 months COBRA, full equity vesting on termination without cause or for good reason.
- Former interim CFO Donegan to provide consulting services as PFO/PAO via MCD Consulting; receives $100k signing fee, $50k/month, and 50,000 RSUs.
- Consulting agreement anticipated to end March 31, 2023; if extended, hourly rate $205.28; additional $100k fee on termination.

## SEC filing metadata
- accession: 0001193125-23-050813
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/0001193125-23-050813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-050813
- JSON: https://secwatch.observer/filing/0001193125-23-050813.json
- Plain text: https://secwatch.observer/filing/0001193125-23-050813.txt

## Key facts
- Executive change
  Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..
  - Action: terminated
  - Role: Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance
  source text: terminated that certain amended and restated employment agreement, dated November 24, 2020, by and between the Company and Mr. Michael Donegan, the Company’s former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/0001193125-23-050813-index.htm
- Executive change
  Michael Donegan was appointed as Principal Financial Officer and Principal Accounting Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Principal Financial Officer and Principal Accounting Officer
  source text: Effective February 21, 2023, the Company entered into a General Consulting and Services Agreement (the “Consulting Agreement”) with MCD Consulting and Management Services, LLC (“MCD”), the manager of which is Mr. Donegan, the Company’s Principal Financial Officer (“PFO”) and Principal Accounting Officer (“PAO”) and former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/0001193125-23-050813-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.